title: Emetine promotes von Hippel-Lindau-independent degradation of hypoxia-inducible factor-2α in clear cell renal carcinoma.
abstract: Inactivating mutations of the von Hippel-Lindau (VHL) tumor suppressor gene are associated with inherited VHL syndrome, which is characterized by susceptibility to a variety of neoplasms, including central nervous system hemangioblastoma and clear cell renal cell carcinoma (CCRCC). Mutations in the VHL gene are also found in the majority of sporadic clear cell renal carcinoma, the most common malignant neoplasm of the human kidney. Inactivation of VHL ubiquitin ligase is associated with normoxic stabilization of hypoxia-inducible factor-1α and 2-α (HIF-1α and HIF-2α), transcriptional regulators of tumor angiogenesis, invasion, survival, and glucose utilization. HIF-2α has been particularly implicated in the development of CCRCC. Although several inhibitors of HIF-1α have been described, these drugs typically have a minimal affect on HIF-2α. 786-O is a VHL-deficient CCRCC cell line that constitutively expresses only HIF-2α and is therefore suitable for the screening of novel HIF-2α inhibitors. Using this cell line, we have identified emetine as a specific inhibitor of HIF-2α protein stability and transcriptional activity. Without altering HIF-2α mRNA level, emetine rapidly and dramatically down-regulated HIF-2α protein expression in 786-O cells. HIF-2α down-regulation was accompanied by HIF-2α ubiquitination and was reversed by proteasome inhibition. Emetine-induced HIF-2α down-regulation was confirmed in three additional VHL-renal cancer cell lines, was insensitive to the prolyl hydroxylase inhibitor dimethyloxaloyl glycine, and did not require neural precursor cell expressed developmentally down-regulated-8, suggesting that emetine accesses a previously undescribed cullin-independent proteasome degradation pathway for HIF-2α. These data support the use of emetine or structurally related compounds as useful leads for the identification of novel HIF-2α inhibitors.
authors.affiliation: Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
authors.forename: Hye-Sik
authors.initials: HS
authors.lastname: Kong
authors.forename: Sunmin
authors.initials: S
authors.lastname: Lee
authors.forename: Kristin
authors.initials: K
authors.lastname: Beebe
authors.forename: Bradley
authors.initials: B
authors.lastname: Scroggins
authors.forename: Gopal
authors.initials: G
authors.lastname: Gupta
authors.forename: Min-Jung
authors.initials: MJ
authors.lastname: Lee
authors.forename: Yun-Jin
authors.initials: YJ
authors.lastname: Jung
authors.forename: Jane
authors.initials: J
authors.lastname: Trepel
authors.forename: Leonard
authors.initials: L
authors.lastname: Neckers
mesh_terms: D051792:Basic Helix-Loop-Helix Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D002292:Carcinoma, Renal Cell / Q000378:metabolism*; D045744:Cell Line, Tumor; D015536:Down-Regulation / Q000187:drug effects; D004640:Emetine / Q000494:pharmacology*; D006801:Humans; D007680:Kidney Neoplasms / Q000378:metabolism*; D051794:Von Hippel-Lindau Tumor Suppressor Protein / Q000502:physiology*; D000099162:Endothelial PAS Domain-Containing Protein 1
chemical_list: D051792:Basic Helix-Loop-Helix Proteins; D004640:Emetine; D051794:Von Hippel-Lindau Tumor Suppressor Protein; D000099162:Endothelial PAS Domain-Containing Protein 1
references.citation: Cancer Res. 2005 Apr 15;65(8):3299-306
references.pmid: 15833863
references.citation: Oncogene. 2008 Sep 11;27(40):5354-8
references.pmid: 18490920
references.citation: Br J Cancer. 2007 Feb 12;96(3):403-7
references.pmid: 17211469
references.citation: Mol Pharmacol. 2006 Nov;70(5):1664-71
references.pmid: 16880289
references.citation: Am J Physiol Renal Physiol. 2004 Jul;287(1):F1-6
references.pmid: 15180922
references.citation: Int J Cancer. 2009 Feb 15;124(4):763-71
references.pmid: 19030186
references.citation: Cancer Res. 2001 Jul 1;61(13):5215-22
references.pmid: 11431362
references.citation: Neuro Oncol. 2005 Apr;7(2):134-53
references.pmid: 15831232
references.citation: Nat Rev Drug Discov. 2006 Aug;5(8):671-88
references.pmid: 16883305
references.citation: J Nat Prod. 2005 Jun;68(6):947-50
references.pmid: 15974627
references.citation: Mol Cell Biol. 2005 Jul;25(13):5675-86
references.pmid: 15964822
references.citation: Nat Rev Cancer. 2003 Oct;3(10):721-32
references.pmid: 13130303
references.citation: Fed Proc. 1973 Jun;32(6):1673-8
references.pmid: 4575885
references.citation: Cancer Cell. 2002 Apr;1(3):237-46
references.pmid: 12086860
references.citation: Nature. 1999 May 20;399(6733):271-5
references.pmid: 10353251
references.citation: Urol Oncol. 2009 May-Jun;27(3):238-45
references.pmid: 19414111
references.citation: Oncogene. 2000 Nov 16;19(48):5435-43
references.pmid: 11114720
references.citation: J Biol Chem. 2007 Jun 8;282(23):17032-40
references.pmid: 17439941
references.citation: Mol Pharmacol. 2004 Sep;66(3):612-9
references.pmid: 15322253
references.citation: Curr Opin Genet Dev. 2010 Feb;20(1):51-6
references.pmid: 19942427
references.citation: Mol Cell Biol. 2005 Apr;25(8):3163-72
references.pmid: 15798202
references.citation: Mol Cell Biol. 2003 Dec;23(24):9361-74
references.pmid: 14645546
references.citation: Cancer Cell. 2005 Aug;8(2):143-53
references.pmid: 16098467
references.citation: Cancer Res. 2005 Jun 1;65(11):4918-28
references.pmid: 15930314
references.citation: Cancer. 2009 May 15;115(10 Suppl):2262-72
references.pmid: 19402056
references.citation: J Biol Chem. 2002 Aug 16;277(33):29936-44
references.pmid: 12052835
references.citation: Cancer Cell. 2002 Apr;1(3):247-55
references.pmid: 12086861
references.citation: J Biol Chem. 2004 Apr 16;279(16):16128-35
references.pmid: 14764593
references.citation: Semin Cancer Biol. 2009 Feb;19(1):12-6
references.pmid: 19114105
references.citation: Nat Med. 2006 Jan;12(1):122-7
references.pmid: 16341243
references.citation: Cancer Res. 2006 Mar 1;66(5):2576-83
references.pmid: 16510575
references.citation: Oncogene. 2008 Feb 28;27(10):1404-11
references.pmid: 17828303
references.citation: Cell Cycle. 2007 Apr 15;6(8):919-26
references.pmid: 17404509
references.citation: Biochem J. 2003 Mar 15;370(Pt 3):1011-7
references.pmid: 12479793
references.citation: J Biol Chem. 2007 Mar 16;282(11):8019-26
references.pmid: 17200123
references.citation: Mol Biol Cell. 2006 Apr;17(4):1549-58
references.pmid: 16421254
references.citation: Cell Signal. 2005 Jan;17(1):1-9
references.pmid: 15451019